Mersana Therapeutics Common Stock Net 2016-2024 | MRSN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Mersana Therapeutics common stock net from 2016 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Mersana Therapeutics common stock net from 2016 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$170.6B
Vertex Pharmaceuticals (VRTX)	$117.1B
Regeneron Pharmaceuticals (REGN)	$111.8B
Bristol Myers Squibb (BMY)	$109.9B
Gilead Sciences (GILD)	$104.8B
CSL (CSLLY)	$95.8B
GSK (GSK)	$79.5B
Alnylam Pharmaceuticals (ALNY)	$34.6B
Argenex SE (ARGX)	$32.5B
BioNTech SE (BNTX)	$28.5B
Biogen (BIIB)	$26.9B
Moderna (MRNA)	$23.5B
BeiGene (BGNE)	$22.7B
Illumina (ILMN)	$21.7B
Genmab (GMAB)	$15.5B
BioMarin Pharmaceutical (BMRN)	$12.9B
Incyte (INCY)	$12.9B
Vaxcyte (PCVX)	$12.4B
Exact Sciences (EXAS)	$12.3B
Insmed (INSM)	$12.3B
Bio-Techne Corp (TECH)	$11.7B
Sarepta Therapeutics (SRPT)	$11.3B
QIAGEN (QGEN)	$9.9B
Bio-Rad Laboratories (BIO.B)	$9.3B
Legend Biotech (LEGN)	$8.7B
Roivant Sciences (ROIV)	$8.3B
Ascendis Pharma (ASND)	$8.2B
Repligen (RGEN)	$7.8B
Revolution Medicines (RVMD)	$7.7B
Halozyme Therapeutics (HALO)	$7.7B